Petros Pharmaceuticals, Inc. expects a recent label comprehension study to move it closer to an Rx-to-OTC switch of its Stendra erectile dysfunction drug, a project it has increased research spending on by nearly $500,000 in the past year.
The New York firm also expects the Drug Facts label technology it’s developing for potential OTC sales of its avanafil ED drug, a phosphodiesterase 5 inhibitor, could be used for...